Logo image of SER

SERINA THERAPEUTICS INC. (SER) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:SER - US81751A1088 - Common Stock

3.1 USD
+0.41 (+15.24%)
Last: 1/16/2026, 8:04:00 PM
Fundamental Rating

2

Taking everything into account, SER scores 2 out of 10 in our fundamental rating. SER was compared to 525 industry peers in the Biotechnology industry. While SER seems to be doing ok healthwise, there are quite some concerns on its profitability. SER is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SER had negative earnings in the past year.
  • In the past year SER has reported a negative cash flow from operations.
  • SER had negative earnings in each of the past 5 years.
  • SER had a negative operating cash flow in each of the past 5 years.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -124.61%, SER is doing worse than 79.62% of the companies in the same industry.
  • SER has a worse Return On Equity (-618.26%) than 76.38% of its industry peers.
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

  • SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SER has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SER has been reduced compared to 5 years ago.
  • SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • SER has an Altman-Z score of -11.62. This is a bad value and indicates that SER is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.62, SER is doing worse than 74.29% of the companies in the same industry.
  • SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.62
ROIC/WACCN/A
WACC8.63%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • SER has a Current Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.24, SER is doing worse than 73.52% of the companies in the same industry.
  • A Quick Ratio of 2.24 indicates that SER has no problem at all paying its short term obligations.
  • SER has a Quick ratio of 2.24. This is in the lower half of the industry: SER underperforms 71.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

  • SER shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.97%, which is quite impressive.
  • Looking at the last year, SER shows a very negative growth in Revenue. The Revenue has decreased by -60.56% in the last year.
  • Measured over the past years, SER shows a very negative growth in Revenue. The Revenue has been decreasing by -49.65% on average per year.
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%

3.2 Future

  • SER is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.12% yearly.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-34.1%
EPS Next 2Y-9.74%
EPS Next 3Y2.15%
EPS Next 5Y3.12%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2033 5M 10M 15M 20M 25M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SER. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.74%
EPS Next 3Y2.15%

More info and screens

0

5. Dividend

5.1 Amount

  • SER does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SERINA THERAPEUTICS INC.

NYSEARCA:SER (1/16/2026, 8:04:00 PM)

3.1

+0.41 (+15.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners4.35%
Inst Owner Change0%
Ins Owners7.28%
Ins Owner Change0%
Market Cap33.05M
Revenue(TTM)56.00K
Net Income(TTM)-11.14M
Analysts80
Price Target13.26 (327.74%)
Short Float %0.65%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16%
Min EPS beat(2)-53.76%
Max EPS beat(2)21.75%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)5.63%
EPS NY rev (3m)5.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 590.11
P/FCF N/A
P/OCF N/A
P/B 18.34
P/tB 18.34
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.01
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.24%
Cap/Sales 96.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -11.62
F-Score3
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
EPS Next Y-34.1%
EPS Next 2Y-9.74%
EPS Next 3Y2.15%
EPS Next 5Y3.12%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-143.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.59%
OCF growth 3YN/A
OCF growth 5YN/A

SERINA THERAPEUTICS INC. / SER FAQ

What is the fundamental rating for SER stock?

ChartMill assigns a fundamental rating of 2 / 10 to SER.


Can you provide the valuation status for SERINA THERAPEUTICS INC.?

ChartMill assigns a valuation rating of 0 / 10 to SERINA THERAPEUTICS INC. (SER). This can be considered as Overvalued.


How profitable is SERINA THERAPEUTICS INC. (SER) stock?

SERINA THERAPEUTICS INC. (SER) has a profitability rating of 0 / 10.


How financially healthy is SERINA THERAPEUTICS INC.?

The financial health rating of SERINA THERAPEUTICS INC. (SER) is 6 / 10.